This segment focuses on the research, development, and commercialization of antiviral therapeutics, with a primary emphasis on TPOXX (tecovirimat) for the treatment of smallpox. R&D activities include exploring new formulations, indications, and delivery methods for TPOXX, as well as identifying and developing novel antiviral compounds to combat emerging infectious diseases. The segment leverages expertise in virology, pharmacology, and drug development to create effective treatments for biothreats and other viral infections. Clinical trials are conducted to evaluate the safety and efficacy of new antiviral candidates. The ultimate goal is to provide effective medical countermeasures to protect public health and national security.

This segment is dedicated to providing comprehensive health security solutions, including the development and distribution of medical countermeasures for biothreats and emerging infectious diseases. It involves strategic partnerships with government agencies, public health organizations, and pharmaceutical companies to ensure the availability and accessibility of critical medicines. The segment focuses on market access, regulatory compliance, and supply chain management to deliver effective solutions to protect public health. Future opportunities include expanding the portfolio of health security products and services to address a wider range of threats, as well as leveraging data analytics and predictive modeling to anticipate and respond to emerging health crises.